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Splicing Regulation in Neurons: Minireview
Tinkering with
Cell-Specific Control
be overlaid (see Figure 1). This arrangement is attractive
because it leads to the prediction that the balance of
regulation can be shifted from one cell type to another
based upon differences in the interacting regulatory fac-
tors. The idea that the balance of control can be shifted
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to positive regulation (exon-selection) in neuronal cells
and to negative regulation (exon-skipping) in nonneu-
ronal cells implies that the neuron-specific exon is not
left unregulated in any cell type. In another sense, theNeurons are rich with examples of regulated alterna-
hypothesis is attractive because it presents a frameworktive splicing events that produce structural changes in
to account for the fine control of splicing events ob-proteins important for the ability of these cells to com-
served in natural systems. The study of developmentallymunicate electrical and chemical signals (ion channels,
induced changes in splicing regulation in the rat cere-receptors, neurotransmitters), and to develop synap-
bellum illustrates the gradual changes, both increasestic connections (neurotransmitter receptors). In some
and decreases in neural exon selection, for a variety ofcases, the change in protein function is known to be
substrates in a time frame that overlaps with synapto-exquisitely specific in affecting the kinetics of ion chan-
genesis (Wang and Grabowski, 1996). These splicingnel gating (Lin et al., 1997) or the location of protein
changes are both coordinated and tissue-specific. Howisoforms at the postsynaptic membrane (Ehlers et al.,
do splicing regulatory pathways respond to develop-1995). In most cases, however, there are changes im-
mental signals? A single cell PCR analysis over the sameposed by splicing for which there are no known func-
time frame further illustrates that there are significant
tional consequences. Understanding the biological im-
differences in the extent of splicing regulation in Purkinje
pact of neuron-specific splicing offers many interesting
and granule neurons and that this effect is gene-specific.
challenges, but this is the tip of the iceberg. Additional Differences in splicing are also noted for distinct neu-
questions of a mechanistic nature drive current research rons of aplysia (Buck et al., 1987). How is splicing regula-
and stimulate ideas in this area. What is the molecular tion adjusted in different neurons? The conclusion from
basis of theneural specificity of splicing? How is splicing these studies is that the biology of regulated splicing
regulation modulated or tuned in different neurons?How events in neurons is more interesting than models of
do developmental programs coordinate splicing regula- on/off regulation would indicate, and this fits well with
tory pathways? more complex scenarios that superimpose positive and
The Complex Language of RNA Regulatory Signals negative control.
and the Importance of Negative Control What is the evidence for the complex arrangement of
From recent studies of cassette exons that are spliced opposing RNA signals and how can we make sense of
in neuronal cells and not in other cell types, one thing this RNA language? A complex arrangement of positive
and negative regulatory RNA signals is illustrated by theis clear. There is no simple answer to the origin of the
N1 exon of c-src and the 24 nucleotide exon of the g2neural specificity of splicing. For the framework of dis-
subunit of the GABAA receptor, both neuron-specificcussion, and with an emphasis on simple, two models
cassette exons. Positive regulatory elements identifiedcan be proposed to account for neuron-specific splicing
by in vivo expression assays in neuronal cell lines areof a cassette exon. Neurons contain a specialized activ-
located near and/or within the neural exon, butare other-ity that promotes selection of the neuron-specific exon,
wise distinct from one another and from known splicingwhereas nonneuronal cells have little or none of this
signals (Black, 1992; Zhang et al., 1996). For c-src, theactivity (positive regulation model). Alternatively, non-
key positive regulatory sequence is an intron enhancerneuronal cellscontain an activity that represses (neuron-
positioned in the downstream intron, whereas for g2, thespecific) exon selection, and this activity is missing or
regulatory region contains an element in the upstreamless abundant in neurons (negative regulation model).
intron and one in the neural exon itself. Despite theWhen taken at face value, the negative regulation model
lack of similarity of the positive signals, the negative
makes the unsettling prediction that specialized factors
elements provide a unifying theme. Two recent studies
in neurons are not necessarily required to account for provide functional evidence for negative regulation
the neural specificity. Rather a difference in the level or (Ashiya and Grabowski, 1997; Chan and Black, 1997).
activity of repressor machineries in neurons may be all In c-src, two repressor signals are localized in the poly-
that is needed to account for the cell specificity. The pyrimidine tract just upstream of the neural exon, and
current status of work in this area, although quantum two additional sites are found in the intron enhancer
jumps away from providing a comprehensive under- region. In g2, three repressor signals surround the
standing of regulatory mechanisms, paints a more inter- branch site of the neural exon and a fourth overlaps with
esting picture than any single model would indicate. a positive element in the neural exon.
The paradigm that emerges from several recent stud- Shifting the Balance to Positive Regulation
ies is that the RNA regulatory regions that encompass in Neurons: hnRNP Proteins
the neuron-specific exon and adjacent intron regions as Splicing Regulators
contain a complex arrangement of opposing signals that The repressor sequences from both c-src and g2 pre-
mRNAs are rich in pyrimidine residues and contain oneallow for positive and negative control mechanisms to
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Figure 1. A Cell-Specific Alternative Splicing Switch Modulated by a Complex Arrangement of Positive and Negative RNA Signals
Schematic illustrates a pre-mRNA region containing a neuron-specific cassette exon (shaded box) and flanking intron/exon regions. RNA
signals that repress splicing of the neural exon bind avidly to the hnRNP protein, PTB. The negative signals are arranged in clusters that
overlap with cell-specific signals required for splicing of the neural exon (RNA regulatory region; thin boxes). The RNA regulatory region
includes binding sites for general splicing components, such as U2 snRNP and U2AF, at the branch site/39 splice site region, as well as U1
snRNP at the 59 splice site. A central question is, how are interactions of general splicing components at the splice sites of the neural exon
modulated by repressors in nonneuronal cells, including PTB, and by activating mechanisms in neurons? Activating factors responsible for
shifting the balance of control to the neural splicing pathway are largely unidentified. KSRP, a KH-type RNA-binding protein, is enriched in
neuronal cells and regulates splicing of the c-src neural exon through recognition of intron enhancer sequences in the downstream portion
of the regulatory region. PTB-binding sites overlap with neuron-specific regulatory signals, including the c-src intron enhancer sequence, and
with the U2AF-binding region. On/off models are not sufficient to account for the gradient of splicing regulation observed for some neural
exons during development, or in distinct neuronal cell types (graph).
or more of the following motifs in a larger pyrimidine reported in studies of muscle-specific splicing events.
So, it is not likely that PTB alone accounts for the neuralcontextÐCUCUCU, UUCUCU, UUCCUU, CUUCUUC.
Repressor sequences in the form of short RNA competi- specificity of splicing. Nonetheless, there is the interest-
ing observation that nuclear extracts derived from rattors function to switch splicing to the neural pathway
when added to HeLa splicing extracts together with brain and neuronal cells in culture express different
forms of PTB, compared to HeLa cells and rat kidneyradiolabeled pre-mRNA. These RNA competitors show
specific binding to the polypyrimidine tract±binding pro- (Ashiya and Grabowski, 1997; Chan and Black, 1997).
Three known isoforms of human PTB have been cloned,tein (PTB), and there is good agreement between the
strength of PTB binding and the magnitude of the splic- PTB1, PTB2, and PTB4/hnRNP I, and these differ in the
length of the linker region between the first and seconding switch. Additional evidence for the involvement of
PTB is provided by gain-of-function experiments in two RNA recognition domains. It is not known if these
isoforms differ in their ability to confer repression, or towhich repression is reestablished by addition of excess
PTB together with the RNA competitor. These results interact with protein partners. If there is truly a different
distribution of PTB isoforms in neurons (the precise dif-demonstrate a requirement for PTB, but do not address
whether PTB is sufficient to establish repression. More ferences in protein structure and distribution need to
be nailed down further), the question of functional differ-rigorous tests need to be applied to address this issue
and to assess the relevance of these repressive mecha- ences in repression for the various isoforms will be espe-
cially relevant to address.nisms to living cells.
The mechanism by which the RNA competitors drive PTB is a member of the large family of hnRNP proteins,
originally viewed in electron micrographs as beads onthe dissociation of PTB from pre-mRNA repressor sites
is likely tooccur by simple mass action. Once the repres- a string in their association with nuclear pre-mRNA (see
Dreyfuss et al., 1993, for review). An earlier hypothesissor sites are vacated, the overlapping positive signals
are made available for interaction with general splicing that hnRNP particles are nonspecific structures to com-
pact and protect RNA from nucleolytic degradation hasfactors in the HeLa extract. For g2 pre-mRNA, neuron-
specific factors have not yet been identified, and it is long been held as too narrow a view. A variety of hnRNP
proteins are known to bind at specific RNA sequences,too early to rule out a simple derepression model in
neuronal cells. including pre-mRNA splice sites, and some are splicing
regulators. The involvement of PTB in splicing repres-How do mechanisms of repression, and PTB effects
in particular, account for the neural specificity of splic- sion lends further strength to the idea that ªhnRNP struc-
tureº is both specific and dynamic, and calls to minding? It is important to point out that the evidence for
the involvement of PTB in splicing repression was first an obvious analogy to chromatin. Some neuronal cells
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might contain lower levels of PTB, or an altered distribu- correlation between specificsplicing defects and human
disease. These previous reports show that mutations intion of isoforms. Alternatively, there might be activities in
neuronal cells that disrupt splicing repressor complexes splice sites, or in internal intron regions, exist in the
chromosomal copy of the gene, and it is virtually certainafter their assembly with pre-mRNA, analogous to the
disruption of nucleosomes at promoter sites during tran- that these mutations account for the aberrant splicing
events. What is striking about the Lin et al. (1998) studyscriptional activation.
An important advance in the field is represented by is that there are multiple splicing defects that do not
correlate with any mutations in the EAAT2 gene. Thethe discovery of the neural splicing regulator, KSRP,
which binds to the intron enhancer region of the c-src sequences of the splice site regions were checked with
particular care and found to be intact. Moreover, thesepre-mRNA and mediates splicing of the neural exon (Min
et al., 1997). The identification of KSRP stems from a defects show a striking regional specificity in the brain.
Splicing defects in EAAT2 mRNA are observed in post-careful analysis of protein components that assemble
in neuronal nuclear extracts with a short RNA contain- mortem samples of the motor cortex, but not in the
cerebellum or hippocampus of the same individuals.ing the core intron enhancer sequence. KSRP is en-
riched, but not exclusively expressed, in neuronal cells, These defects are not found in normal brain or in individ-
uals with neurodegenerative diseases other than ALS.and additional components of the complex, including
hnRNP F, are ubiquitously expressed. The sequence of Interest in the cellular (astrocyte) specificity of the de-
fects is tempered by the fact that the expression ofKSRP shows that it contains unusual RNA-binding mo-
tifs of the KH type and bears similarity to hnRNP K. This EAAT2 (mRNA and protein) is known to be restricted to
astrocytes in the brain.similarity to hnRNP K and a distribution among different
cell types suggest that KSRP is an hnRNP-type of splic- How strong is the evidence for splicing defects in
EAAT2 mRNA? This study employs the reverse-tran-ing regulator. Although not exclusively neuronal, higher
levels of KSRP in neurons might shift the balance of scriptase polymerase chain reaction to amplify EAAT2
mRNA sequences using as template poly(A)1 mRNAcontrol by engaging positive RNA signals at the expense
of repressor binding. The fact that the c-src intron en- from the motor cortex of individuals with ALS. Multiple
specific exon deletions are found from sequencing thehancer contains two repressor sequences suggests that
KSRP mustsomehow displace or competefor PTB bind- cloned DNA products, whereas the full-length cDNA is
amplified from other brain regions of the same individualing to the regulatory region. Current evidence indicates
that KSRP functions in conjunction with a specific sub- or from normal control samples. Similar EAAT2 mRNA
defects are observed from 19 additional patients withset of intron enhancers, which suggests that the regula-
tory functions of this protein are highly specific. Several ALS, and these too are restricted to the motor cortex.
Nuclease S1 analysis provides additional evidence forcomprehensive reviews describe the properties of dis-
tinct splicing enhancer elements and their interacting specific splicing defects that result in exon skipping.
When these results are quantified an impressive fractionproteins (Fu, 1995; Manley and Tacke, 1996). In addition,
one recent study describes a complex intron enhancer (70%) of the EAAT2 mRNA is found to be defective.
Two specific mRNA defects stand out in this study.involved in the activation of neuron-specific processing
of calcitonin/CGRP pre-mRNA (Lou et al., 1996). In the One is exon 9 skipping (there are 11 EAAT2 exons).
Another is intron 7 retention. These defects are the oneslatter case, the intron enhancer directs positive regula-
tion of polyadenylation and contains specific binding most commonly observed and in 8 out of 30ALS patients
they are found together. What mechanism accounts forsites for PTB.
Aberrant Splicing in Astrocytes, Neurodegenerative these tissue- and RNA sequence±specific defects? A
gross defect in a major splicing component, such asDisease, and More RNA-Binding Proteins
The current issue of Neuron reports the identification of a spliceosomal snRNP, does not provide a satisfying
explanation, since this would be expected to have dras-aberrant splicing events in human brain (Lin et al., 1998)
that may have particular relevance to the paradigms of tic effects on the catalysis of other splicing events in
the EAAT2 transcript. Another unlikely explanation is aregulated splicing mechanisms described above. This
study shows a close correlation between the defects in defect in the machinery (snRNPs and auxillary proteins)
that allows for splice site selection and exon definition,splicing of the glutamate transporter, EAAT2, and the
sporadic form of the neurodegenerative disease, amyo- since thesetoo, aregeneral features of splicing (informa-
tive reviews on these topics are available: Berget, 1995;trophic lateral sclerosis (ALS). Inappropriate exon-skip-
ping events figure prominently in the types of defects Black, 1997). Recent studies that address the molecular
basis of spinal muscular atrophy make a connectionobserved. An additional defect is characterized by an
mRNA with a retained intron and poly(A) tail, suggesting between a defect in an RNA-binding protein, survival of
motor neurons protein (SMN), and pathways of snRNPthat inappropriate polyadenylation may also be part of
the equation. From a disease standpoint, the connection biogenesis (see, for example, Fischer et al., 1997). But
even a defect in snRNP biogenesis would appear to bebetween loss of the EAAT2 protein and motor neuron
degeneration is satisfying. Glutamate transporters are too general to account for the specific splicing defects
reported in the ALS study. The Lin et al. (1998) studyrequired to move glutamate into cells where it can be
metabolized, and astrocytes are factories that do this reports that another glutamate transporter, EAAT1 pro-
tein, is expressed normally in ALS patients, which mustjob. Otherwise, no extracellular mechanisms exist to
perform this function. A buildup of glutamate in the ex- mean that EAAT1 pre-mRNA is spliced and polyade-
nylated normally. The EAAT1 gene has an intron/exontracellular space is deadly for cells in the immediate
vicinity, especially motor neurons. structure similar to EAAT2. The observation that EAAT1
is normal argues for at least some pre-mRNA substrateThere is a large body of literature documenting the
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Ehlers, M.D., Tingley, W.G., and Huganir, R.L. (1995). Science 269,specificity. Nonetheless the study leaves us wondering
1734±1737.whether there are specific splicing defects in other
Fischer, U., Liu, Q., and Dreyfuss, G. (1997). Cell 90, 1023±1029.mRNAs, or if EAAT2 is the particular target.
Fu, X.-D. (1995). RNA 1, 663±680.It is interesting to speculate that the defect in question
Lin, Z., Haus, S., Edgerton, J., and Lipscombe, D. (1997). Neuroninvolves an RNA-binding protein with both a specific
18, 153±166.RNA binding preference and tissue-specific expression
Lin, C.-L.G., Bristol, L.A., Jin, L., Dykes-Hoberg, M., Crawford, T.,pattern. Hu RNA±binding proteins, for example, are ex-
Clawson, L., and Rothstein, J.D. (1998). Neuron, 20, 589±602.clusively neuronal and show region- and cell-specific
Lou, H., Gagel, R.F., and Berget, S.M. (1996). Genes Dev. 10,expression patterns in mammalian brain (Okano and
208±219.
Darnell, 1997). In addition, the distribution and levels of
Manley, J.L., and Tacke, R. (1996). Genes Dev. 10, 1569±1579.Hu proteins change during development. The specific
Min, H., Turck, C.W., Nikolic, J.M., and Black, D.L. (1997). Genesfunctions of Hu proteins are not known, but their link to
Dev. 11, 1023±1036.
neurodegenerative disease argues that these proteins
Okano, H.J., and Darnell, R.B. (1997). J. Neurosci. 17, 3024±3037.
must have important roles in the development and func-
Sakakibara, S., and Darnell, R.B. (1997). J. Neurosci. 17, 8300±8312.tion of neurons. Nova-1 is a distinct family of neuron-
Wang, Z., and Grabowski, P.J. (1996). RNA 2, 1241±1253.specific RNA-binding proteins that binds to specific
Zhang, L., Ashiya, M., and Grabowski, P.J. (1996). RNA 2, 682±698.RNA structures found in introns of the glycine receptor
and the Nova-1 pre-mRNA itself (Buckanovich and Dar-
nell, 1997). The similarity of Nova-1 to KH-type splicing
regulators suggests that it might function as a splicing
regulator in specific neurons of mammalian brain. Fi-
nally, a third type of RNA-binding protein, m-Msi-1, is
brain-specific with an expression pattern in the adult
that is astrocyte-specific (Sakakibara and Darnell, 1997).
The RNA-binding proteins discussed above were dis-
covered by the use of antisera from patients with neuro-
degenerative disease. How many other brain-specific
proteins remain obscure for the lack of molecular probes?
Even if the ALS splicing defects are explained by a
specific change in the level or activity of an RNA-binding
protein, and that is a big if, the underlying molecular
mechanism might be subtle and difficult to detect. Even
a subtle change in the function of a splicing regulator
might be all that it takes to shift the balance of control
to disaster. A specific exon-skipping defect for EAAT2
could be due to a decrease in positive regulation, or to
the heightened activity of a splicing repressor. In either
case, the authors will need a lucky break to identify the
molecular cause of this unusually novel splicing defect.
Perhaps it would be worth the chance to test some
of the patient antisera reactive for brain-specific RNA-
binding proteins to see if aberrant protein forms or ex-
pression patterns are evident. It was not long ago that
the use of antisera from patients with autoimmune dis-
ease resulted in thegrand discovery of the spliceosomal
snRNPs. From this discussion there is reason to hope
that a better understanding of the molecular basis of
neurodegenerative disease will lead both to therapeutic
advances and to insights into the inner workings of splic-
ing control.
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